pembrolizumab
Keytruda Receives Traditional Approval for Some Patients With HER2-Positive Gastric or GEJ Adenocarcinoma
The FDA has approved pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the ...
MARCH 28, 2025
FDA Approves Keytruda With Chemotherapy for Biliary Tract Cancer
The FDA approved pembrolizumab (Keytruda, Merck) to be used with gemcitabine and cisplatin for locally advanced, ...
NOVEMBER 16, 2023
FDA Amends Keytruda’s Gastric Cancer Indication
On Nov. 7, 2023, the FDA revised the existing indication of pembrolizumab (Keytruda, Merck) with trastuzumab-, ...
NOVEMBER 14, 2023
Keytruda Approved for First-Line Treatment of Advanced or Metastatic HER2+ GI Cancers
The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) in combination with trastuzumab and ...
MAY 7, 2021
FDA Approves Keytruda to Treat Esophageal and GEJ Cancers
The FDA approved pembrolizumab (Keytruda, Merck) in combination with platinum- and fluoropyrimidine-based ...
APRIL 6, 2021
First PD-1 Agent OK'ed for Initial MonoRx for Some Patients With Advanced CRC
The FDA approved pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with unresectable or ...
JULY 31, 2020
First PD-1 Agent OK'ed for Initial MonoRx for Some Patients With Advanced CRC
The FDA approved pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with unresectable or ...
JULY 9, 2020
Keytruda Granted Accelerated Approval for Treatment of HCC
The FDA expanded the approved indications for pembrolizumab (Keytruda, Merck), granting the checkpoint inhibitor ...
NOVEMBER 26, 2018
Keytruda Approved for Any Solid Tumor With Specific Biomarker
The FDA has approved pembrolizumab (Keytruda, Merck) for the treatment of adults and children with unresectable or ...
JULY 24, 2017
